March 7 (Reuters) - Mesoblast Ltd MSB.AX
* FDA grants Mesoblast fast track designation for GVHD
* FDA grants fast track designation for Mesoblast's cell therapy in children with Acute Graft Versus Host Disease Source text for Eikon: ID:nASXc7D4C3 Further company coverage: MSB.AX